Certara, Inc. filings document the public-company record for a Nasdaq-listed provider of biosimulation software and model-informed drug development services. Its 8-K reports include operating and financial results, guidance-related exhibits, material-event disclosures, credit agreement amendments and the completed sale of its global medical writing and related regulatory services business.
Proxy and governance filings describe annual-meeting matters, board composition, executive transitions and stockholder voting procedures. The record also identifies Certara's common stock, capital-structure disclosures and clinical or regulatory disclosures tied to software, services, regulatory science and clinical-development support.
Certara, Inc. reported that executive Robert Aspbury, President of Predictive Tech, received new equity awards on May 11, 2026. He was granted 129,629 Performance Stock Units (PSUs) and two Restricted Stock Unit (RSU) awards covering 246,913 and 86,419 underlying shares of common stock.
Footnotes explain that PSUs can pay out between 0% and 200% of the target amounts based on Certara’s total shareholder return through periods ending March 31, 2028 and March 31, 2029. The RSUs vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. A separate block of 68,348 PSUs was granted and then fully canceled in an issuer disposition, reflecting an amendment of earlier awards.
Certara, Inc. reported equity compensation changes for President and Chief Commercial Officer Leif E. Pedersen. On May 11, 2026, he received grants of 111,111 performance stock units and 74,074 restricted stock units at no cash cost, each unit tied to one share of common stock or its cash equivalent.
The new performance stock units can ultimately deliver between 0% and 200% of the target share amount based on Certara’s total shareholder return through periods ending on March 31, 2028 and March 31, 2029 under the company’s long-term incentive plans. The restricted stock units are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also shows a prior grant of 68,348 performance stock units was returned to the issuer, leaving no units outstanding from that earlier award.
Certara, Inc. reported compensation-related equity awards for Chief Human Resources Officer Rona Anhalt. On May 11, 2026, she received grants of 92,592 performance stock units and 61,728 restricted stock units, each representing rights to receive shares of common stock under the company’s 2020 Incentive Plan.
The PSUs can ultimately pay out between 0% and 200% of the target amount based on Certara’s total shareholder return over performance periods ending on March 31, 2028 and March 31, 2029. The RSUs are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also records a 43,938-unit PSU disposition to the issuer, reducing that specific grant’s balance to zero.
Certara, Inc. CEO Jon Matthew Resnick reported equity compensation activity and related tax withholding. On May 11, 2026, he exercised 59,766 restricted stock units into common shares and 24,377 shares were withheld at $6.31 per share to cover tax obligations, leaving 35,389 common shares directly held.
On the same date, he received several new awards under the 2020 Incentive Plan: 728,405 RSUs vesting in 2027 and 2028, 493,827 RSUs vesting in 2027 and 2029, and 179,299 RSUs with tranches through 2029. He was also granted 740,740 and 268,949 performance stock units that can pay out between 0% and 200% of target if Certara’s stock reaches specified price thresholds by April 1, 2028 and March 31, 2029.
Certara, Inc. reported new equity awards for SVP and General Counsel Daniel Corcoran. On May 11, 2026, he received grants of 111,111 performance stock units and 74,074 restricted stock units, each representing rights to receive common shares under the company’s 2020 Incentive Plan.
The PSUs can ultimately settle at 0% to 200% of the target amounts based on Certara’s total shareholder return through periods ending March 31, 2028 and March 31, 2029. The RSUs are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also records a 48,820‑unit PSU grant and a matching 48,820‑unit disposition back to the issuer.
Certara, Inc. Chief Financial Officer John E. Gallagher reported equity-based compensation awards tied to the company’s long-term incentive plans. On May 11, 2026, he received grants of 194,444 performance stock units and 129,629 restricted stock units, each representing rights to receive common shares at no purchase price.
The restricted stock units are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. He also received an additional 102,522 performance stock units grant and simultaneously reported a disposition of a prior 102,522 performance stock units award back to the issuer, leaving no remaining units from that earlier grant. The new performance stock units can ultimately deliver between 0% and 200% of the target share amounts based on total shareholder return performance through periods ending March 31, 2028 and March 31, 2029.
Certara, Inc. reported flat revenue but a swing to loss in its latest quarter. For the three months ended March 31, 2026, revenue was $106.9 million, up slightly from $106.0 million a year earlier, while net results moved from $4.7 million profit to a $8.8 million loss, or basic and diluted loss of $0.06 per share.
Operating income declined to a $4.3 million loss as general and administrative and research and development expenses increased. Cash and cash equivalents fell from $189.4 million at year-end to $149.5 million, driven largely by $40 million of share repurchases and ongoing investment in software development.
The company ended the quarter with $294.8 million of term-loan debt and total stockholders’ equity of $1.02 billion. Bookings were $115.3 million with a software net retention rate of 106.1%, indicating expansion within the existing customer base. After quarter end, Certara closed the sale of its global medical writing and related regulatory services business, expecting to recognize a loss estimated between $28.9 million and $53.7 million on that divestiture.
Certara, Inc. reported first quarter 2026 revenue of $106.9 million, up 1% year over year, with 7% growth in software offset by a 4% decline in services. The company swung to a net loss of $8.8 million versus $4.7 million of net income a year earlier, mainly due to higher operating expenses.
Certara closed the sale of its global medical and regulatory writing business to Veristat for $85 million in cash, plus $15 million in escrow and up to $35 million in potential earn-out. Full-year 2026 guidance now calls for $395–$405 million of revenue and adjusted EBITDA margin of about 30%–32%.
Certara, Inc. has entered into a definitive agreement to sell its global Regulatory and Medical Writing business to Veristat. The deal values the business at up to $135 million, including $100 million in cash at closing, subject to customary working capital and other adjustments, plus up to $35 million of contingent earn-out based on future performance. Up to $15 million of the closing payment may be placed in escrow until certain items are satisfied.
The business generated $50 million of revenue and $17 million of adjusted EBITDA in 2025 and includes approximately 220 employees. Certara describes the divestiture as sharpening its focus on Model-Informed Drug Development and Clinical Intelligence, and plans to update its 2026 guidance after the transaction closes, which is expected in the second quarter of 2026, subject to customary conditions.
Wasatch Advisors files an amendment to its Schedule 13G/A reporting beneficial ownership of 5,272,166 shares of Certara Inc. This position represents 3.3% of the outstanding common stock and shows sole voting power over 3,598,349 shares and sole dispositive power over all 5,272,166 shares. The filing is signed by the reporting CEO on 04/06/2026.